市场调查报告书
商品编码
1403487
到 2030 年器官保存解决方案市场预测:按解决方案、保存类型、器官、最终用户和地区进行的全球分析Organ Preservation Solution Market Forecasts to 2030 - Global Analysis By Solution, Preservation Type, Organ, End User and by Geography |
根据 Stratistics MRC 的数据,2023 年全球器官保存解决方案市场规模为 2.7864 亿美元,预计预测期内复合年增长率为 8.8%,到 2030 年将达到 5.0285 亿美元。
器官保存溶液能够在器官捐赠和移植之间的关键时期维持器官的活力,这使得器官保存溶液对于移植医学至关重要。这些专门的解决方案提供了理想的保存环境,以保护器官免受缺血性损伤。这些解决方案有助于维持细胞完整性并防止细胞肿胀。
根据美国疾病管制与预防美国(CDC) 2020 年的估计,三分之一的糖尿病成人和五分之一的高血压成人可能患有慢性肾臟病。根据 2021 年 CDC 报告,美国每年有 15% 的人患有慢性肾臟病。
由于导致器官衰竭的慢性疾病的增加,以及手术方法和免疫抑制药物的改进,世界各地的器官移植率正在以不可阻挡的速度增加。此外,不断增长的需求凸显了器官保存解决方案对于移植手术的生存和成功至关重要,因此,我们正在努力增强和优化这些针对不同器官类型的解决方案,研究和开发正在进行中。
对于某些器官来说,儘管该领域取得了进展,但目前的器官保存方法可能会限制其存活,特别是在长期保存时。各种器官的复杂性及其不同的生理需求使得很难发展出普遍有效的解决方案。此外,需要继续研究以全面了解每个器官的独特储存要求并提高当前配方的功效,以解决此限制。
只要冷冻保存技术不断进步,器官保存市场就有望成长。冷冻保护剂和冷冻技术的进步可以延长器官保存时间并增加长期保存的可行性。此外,这将导致更灵活的器官移植安排和改进的后勤管理。
缺乏既定的器官保存协议给该行业带来了障碍和风险。医疗机构和地区之间不同的协议可能会阻碍沟通并导致保留结果不一致。此外,建立广泛认可的标准对于确保器官保存技术的可靠性和效率至关重要。
器官保存市场在多个方面受到了 COVID-19大流行的影响。器官移植手术受到影响,导致移植数量减少。这些因素包括医疗保健系统的中断、后勤挑战以及管理流行病的优先事项的转变。器官移植因关闭、旅行限制和获得医疗保健的机会有限而受到阻碍。此外,为了应对医疗保健预算和资源的财务压力,器官保存的研究和发展也在改变。
威斯康辛大学解决方案 (UW) 部门预计将占据最大的市场占有率。肾臟、肝臟和胰臟器官移植经常使用 UW 溶液进行,UW 溶液是一种高效且适应性强的器官保存介质。由于其渗透压、平衡的电解质成分以及减少细胞水肿的能力,建议将其作为器官获取和移植之间关键时期器官保存的选择。此外,该产品的广泛接受度是由于成功的移植、悠久的临床使用历史以及保持器官活力的记录。
器官保存市场在专科诊所中以最高的复合年增长率成长。更专业的医疗保健服务趋势以及对有针对性的、以患者为中心的护理日益增长的需求推动了专门从事器官移植和器官保存的专科诊所的增长。移植前评估、器官保存技术和移植后护理只是这些诊所提供的广泛服务的一小部分。此外,随着器官衰竭的日益普遍和移植技术的进步,患者正在寻求专业诊所的专业知识,这些诊所通常提供比传统医院更有效和个体化的护理。
北美在器官保存解决方案市场中占有最大份额。这项优势是由多种因素促成的,包括发达的医疗保健系统、高频率的器官移植以及医学和技术的进步。此外,该地区凭藉强大的法规环境、广泛的研发支出以及积极采用尖端医疗保健解决方案,处于行业前沿。
亚太地区在器官保存解决方案市场的复合年增长率最高。许多因素正在推动该地区的快速成长,包括器官衰竭盛行率的增加、社会对器官移植的认识以及医疗基础设施的进步。此外,亚太地区市场占有率的成长不仅得益于器官保存技术的进步,还得益于对医疗旅游的日益关注。
According to Stratistics MRC, the Global Organ Preservation Solution Market is accounted for $278.64 million in 2023 and is expected to reach $502.85 million by 2030 growing at a CAGR of 8.8% during the forecast period. Organ Preservation Solution has the ability to preserve organ viability during the crucial time between donation and transplantation, organ preservation solutions are essential to transplant medicine. The ideal preservation environment is provided by these specialized solutions, which are made to shield organs from ischemia damage. These solutions aid in preserving cellular integrity and preventing cellular swelling.
According to the estimates by the Centers for Disease Control and Prevention (CDC) in 2020, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. Per the CDC report issued in 2021, ~15% of people in the US suffer from chronic renal disease each year.
The world's organ transplantation rate is increasing at an unstoppable rate due to an increase in chronic diseases that cause organ failure as well as improvements in surgical methods and immunosuppressive medications. Additionally, the growing demand highlights how vital organ preservation solutions are to the survival and success of transplant operations, which in turn drives ongoing research and development endeavors to enhance and optimize these solutions for a variety of organ kinds.
The viability of some organs may be limited by some current organ preservation methods, even with advancements in the field, especially when done for prolonged periods of time. Developing universally effective solutions is challenging due to the complexity of various organs and their distinct physiological requirements. Furthermore, a comprehensive grasp of the preservation requirements unique to each organ and continuous research to improve the effectiveness of current formulations are necessary to address this constraint.
The organ preservation market is expected to grow as long as cryopreservation technology continues to progress. The prolongation of organ preservation periods and the enhancement of long-term storage feasibility can be possible through advancements in cryoprotectants and freezing techniques. Moreover, this can lead to more flexible organ transplant scheduling and improved logistical management.
The lack of established procedures for organ preservation creates obstacles and risks for the industry. Disparate protocols among healthcare facilities and geographical areas could impede communication and lead to inconsistent preservation results. Additionally, the establishment of widely recognized standards is essential to guaranteeing the dependability and efficiency of organ preservation techniques.
The market for organ preservation has seen a variety of effects from the COVID-19 pandemic. Organ transplantation procedures have been impacted, which has resulted in a decrease in transplant volumes. These factors include disruptions in healthcare systems, logistical difficulties, and a shift in priorities towards managing the pandemic. Organ transplantation has been hampered by lockdowns, travel restrictions, and limited access to healthcare. Furthermore, research and development for organ preservation solutions have also seen changes in response to the financial strain on healthcare budgets and resources.
It is projected that the University of Wisconsin Solution (UW) segment will command the largest market share. Organ transplants for the kidney, liver, and pancreas are frequently performed using the UW solution, an extremely effective and adaptable organ preservation medium. Because of its osmotic pressure, balanced electrolyte composition, and capacity to reduce cellular edema, it is the recommended option for organ preservation during the crucial time between organ procurement and transplantation. Moreover, its broad acceptance can be attributed to its successful transplantation outcomes, long history of clinical use, and track record of preserving organ viability.
The market for organ preservation is growing at the highest CAGR in specialty clinics. The growth of specialty clinics devoted to organ transplantation and preservation is facilitated by the trend toward more specialized healthcare services as well as the rising need for targeted, patient-centered care. Pre-transplant evaluations, organ preservation techniques, and post-transplant care are just a few of the extensive services provided by these clinics. Additionally, patients are seeking the expertise of specialized clinics, which often offer more efficient and personalized care than traditional hospitals, due to the increasing prevalence of organ failure conditions and advancements in transplantation techniques.
In the market for organ preservation solutions, North America holds the largest share. Numerous factors contribute to this dominance, such as a well-developed healthcare system, a high frequency of organ transplant procedures, and ongoing advancements in medical science and technology. Furthermore, the region is at the forefront of the industry because of its strong regulatory environment, large R&D expenditure, and proactive adoption of cutting-edge healthcare solutions.
In the market for organ preservation solutions, the Asia-Pacific region has the highest CAGR. A number of factors, including an increase in the prevalence of organ failure conditions, public awareness of organ transplantation, and advancements in healthcare infrastructure, are driving this region's rapid growth. Furthermore, the growing market share in the Asia-Pacific region can be attributed to the growing emphasis on medical tourism as well as advancements in organ preservation techniques.
Some of the key players in Organ Preservation Solution market include Paragonix Technologies, Inc, Organox Limited, Transmedics, Inc., Bridge to Life Ltd, Transplant Biomedicals, Accord Healthcare Inc., Waters Medical Systems LLC, Preservation Solutions, Inc. and Xvivo Perfusion AB.
In August 2023, US-based commercial medical group TransMedics Group announced the completion of the full acquisition of Summit Aviation, a premier US charter flight operator. The acquisition establishes TransMedics Aviation as the first integrated national provider of air logistics dedicated exclusively to organ transplantation in the US.
In July 2023, Organox Ltd. raised £25 million in a funding round that will allow the company to expand its operations in the U.S. on the back of significantly increasing demand from transplant centers, Oern Stuge, executive chairman, at Organox told BioWorld. The Oxford, U.K.-based company which makes systems to preserve and transport livers for transplant is also preparing for its eventual listing on Nasdaq, he added.
In March 2023, Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies' commercial footprint, including its ongoing extension of clinical service offerings and inventory expansion, and will enable the Company to further advance transplant innovations.